FINV vs. ASND

Last updated Apr 1, 2026

Compare and contrast key facts about FinVolution Group (FINV) and Ascendis Pharma A/S (ASND).

Performance

FINV vs. ASND - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in FinVolution Group (FINV) and Ascendis Pharma A/S (ASND). The values are adjusted to include any dividend payments, if applicable.

FINV vs. ASND - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
FINV FinVolution Group	-8.41%	-20.07%	45.47%	4.39%	6.39%	89.23%	8.51%	-22.85%	-49.37%	-45.64%
ASND Ascendis Pharma A/S	7.26%	54.89%	9.31%	3.13%	-9.22%	-19.34%	19.88%	122.06%	56.39%	10.88%

Fundamentals

Market Cap FINV : $1.27B ASND : $14.04B
EPS FINV : $9.51 ASND : -$3.67
PS Ratio FINV : 0.09 ASND : 19.79
Total Revenue (TTM) FINV : $13.53B ASND : $717.81M
Gross Profit (TTM) FINV : $10.64B ASND : $619.30M
EBITDA (TTM) FINV : $3.00B ASND : -$80.69M

Returns By Period

In the year-to-date period, FINV achieves a -8.41% return, which is significantly lower than ASND's 7.26% return.

FINV

• 1D: 1.70%
• 1M: -14.77%
• YTD: -8.41%
• 6M: -35.01%
• 1Y: -48.38%
• 3Y*: 9.76%
• 5Y*: -2.92%
• 10Y*: —

ASND

• 1D: 4.75%
• 1M: -2.04%
• YTD: 7.26%
• 6M: 15.05%
• 1Y: 46.75%
• 3Y*: 28.73%
• 5Y*: 11.89%
• 10Y*: 28.43%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

FINV vs. ASND — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FINV

FINV Risk / Return Rank: 8
FINV Sharpe Ratio Rank: 4
FINV Sortino Ratio Rank: 6
FINV Omega Ratio Rank: 7
FINV Calmar Ratio Rank: 10
FINV Martin Ratio Rank: 14

ASND

ASND Risk / Return Rank: 82
ASND Sharpe Ratio Rank: 81
ASND Sortino Ratio Rank: 77
ASND Omega Ratio Rank: 72
ASND Calmar Ratio Rank: 90
ASND Martin Ratio Rank: 88

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

FINV vs. ASND - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for FinVolution Group (FINV) and Ascendis Pharma A/S (ASND). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	FINV	ASND	Difference
Sharpe ratio Return per unit of total volatility	-1.01	1.29	-2.30
Sortino ratio Return per unit of downside risk	-1.49	1.95	-3.44
Omega ratio Gain probability vs. loss probability	0.82	1.23	-0.40
Calmar ratio Return relative to maximum drawdown	-0.87	3.96	-4.83
Martin ratio Return relative to average drawdown	-1.38	9.47	-10.85
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

FINV vs. ASND - Sharpe Ratio Comparison

The current FINV Sharpe Ratio is -1.01, which is lower than the ASND Sharpe Ratio of 1.29. The chart below compares the historical Sharpe Ratios of FINV and ASND, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	FINV	ASND	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-1.01	1.29	-2.30
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.06	0.25	-0.31
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.56	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.11	0.49	-0.60

Correlation

The correlation between FINV and ASND is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

FINV vs. ASND - Dividend Comparison

FINV's dividend yield for the trailing twelve months is around 5.78%, while ASND has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019
FINV FinVolution Group	5.78%	5.30%	3.49%	4.39%	4.13%	3.45%	4.49%	7.17%
ASND Ascendis Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

FINV vs. ASND - Drawdown Comparison

The maximum FINV drawdown since its inception was -89.64%, which is greater than ASND's maximum drawdown of -61.72%. Use the drawdown chart below to compare losses from any high point for FINV and ASND.

Drawdown Indicators

	FINV	ASND	Difference
Max Drawdown Largest peak-to-trough decline	-89.64%	-61.72%	-27.92%
Max Drawdown (1Y) Largest decline over 1 year	-56.42%	-12.09%	-44.33%
Max Drawdown (5Y) Largest decline over 5 years	-70.54%	-60.46%	-10.08%
Max Drawdown (10Y) Largest decline over 10 years	—	-61.72%	—
Current Drawdown Current decline from peak	-54.81%	-5.52%	-49.29%
Average Drawdown Average peak-to-trough decline	-53.77%	-18.90%	-34.87%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.66%	5.06%	+30.60%

Volatility

FINV vs. ASND - Volatility Comparison

FinVolution Group (FINV) has a higher volatility of 20.26% compared to Ascendis Pharma A/S (ASND) at 9.38%. This indicates that FINV's price experiences larger fluctuations and is considered to be riskier than ASND based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	FINV	ASND	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.26%	9.38%	+10.88%
Volatility (6M) Calculated over the trailing 6-month period	37.63%	26.45%	+11.18%
Volatility (1Y) Calculated over the trailing 1-year period	48.08%	36.54%	+11.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	50.51%	48.36%	+2.15%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	72.22%	51.28%	+20.94%

Financials

FINV vs. ASND - Profitability Comparison

The chart below illustrates the profitability comparison between FinVolution Group and Ascendis Pharma A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

FINV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported a gross profit of 2.15B and revenue of 2.98B. Therefore, the gross margin over that period was 72.0%.

ASND - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Ascendis Pharma A/S reported a gross profit of 217.98M and revenue of 245.18M. Therefore, the gross margin over that period was 88.9%.

FINV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported an operating income of 475.99M and revenue of 2.98B, resulting in an operating margin of 16.0%.

ASND - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Ascendis Pharma A/S reported an operating income of 9.80M and revenue of 245.18M, resulting in an operating margin of 4.0%.

FINV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, FinVolution Group reported a net income of 418.85M and revenue of 2.98B, resulting in a net margin of 14.1%.

ASND - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Ascendis Pharma A/S reported a net income of -33.25M and revenue of 245.18M, resulting in a net margin of -13.6%.